Skip to main content

Navigation group

Type at least 3 characters
507 articles

Articles

Study Protocol

Published on 15 Jul 2022

Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods

in Aging Psychiatry

  • Marieke J. Henstra
  • Thomas C. Feenstra
  • Rob M. Kok
  • Harm-Pieter Spaans
  • Eric van Exel
  • Annemiek Dols
  • Mardien Oudega
  • Anton C. M. Vergouwen
  • Adriano van der Loo
  • Pierre M. Bet
Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods
Frontiers in Psychiatry
doi 10.3389/fpsyt.2022.953686
  • 3,126 views